Could your gut bugs predict cancer treatment success?
NCT ID NCT07498920
Summary
This study aims to understand if the types of bacteria in a patient's gut (the microbiome) influence how well they respond to a lymphoma drug called glofitamab. Researchers will observe 30 patients with a specific type of lymphoma (DLBCL) who are already scheduled to receive this treatment. They will collect stool samples over a year to see if changes in gut bacteria correlate with treatment effectiveness and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.